When surgeons become patients, they choose the

Light Adjustable Lens™

The Light Adjustable Lens™ (LAL®) is the first and only FDA-approved intraocular lens (IOL) that can be customized after cataract surgery—and when surgeons face that decision themselves, it’s the lens they choose. That says everything.

An IOL Surgeons Trust for Their Own Eyes

Unlike standard IOLs—set to a fixed power before the eye has fully healed—the LAL can be fine-tuned postoperatively through a series of brief, non-invasive light treatments. For surgeons who’ve spent careers working around the limitations of fixed optics, that distinction matters.

If you’re evaluating the LAL for your practice, contact us for more information to help you move forward.

How the Light Adjustable Lens Is Different

The Light Adjustable Lens has transformed cataract surgery by shifting crucial decisions regarding final lens power to the more ideal post-surgery period. This approach allows for unparalleled precision, as it accounts for lens shift and refractive changes that can occur during the healing process to achieve the best possible outcomes.

The innovative Light Adjustable Lens represents a departure from the usual practice of selecting a pre-manufactured lens power before surgery to predict a patient’s post-surgery visual outcome. The accuracy of vision achieved with the postoperative adjustability of the Light Adjustable Lens compared to traditional premium IOLs has been demonstrated in clinical studies.

The Light Adjustable Lens corrects as low as 0.50 D of astigmatism, which is the lowest level approved to be treated.
Q&A Bubbles

How does the Light Adjustable Lens address residual astigmatism?

Residual astigmatism after cataract surgery is a common source of patient dissatisfaction with fixed IOLs. The LAL adjustment process allows cylinder correction postoperatively—after the eye has stabilized—rather than relying on preoperative biometry alone. For patients with complex refractive history or unpredictable measurements, the post-surgical adjustment window provides a precision mechanism that fixed lenses cannot offer.
The Light Adjustable Lens offers LASIK-like accuracy in cataract surgery.2,3
The Light Adjustable Lens provides optimized vision for patient satisfaction.2

Adjust for Infinite Possibilities

The Light Adjustable Lens is a versatile premium lens that a growing number of surgeons are finding is customizable for many types of patients. Throughout the adjustment process, Light Adjustable Lens patients are engaged and participate in their care in a way other lenses can’t offer.

This truly customized approach has led to outcomes they and their doctors are excited about. Almost daily, we add to the list of clinics nationwide that are successfully integrating the Light Adjustable Lens into their workflow and finding that it is a worthwhile investment for their practices and their patients.

0 %
willingness to recommend the Light Adjustable Lens4
0 %
would choose the Light Adjustable Lens for themselves, over any other lens4

How the Light Adjustable Lens Works

The Light Adjustable Lens is implanted using a standard cataract procedure. Patients then experience their vision and surgeons can adjust the lens over a series of treatments to ensure each patient achieves vision that matches their lives. Each adjustment is an ultraviolet (UV) light treatment performed by the Light Delivery Device™ (LDD™) that corrects refractive error and dials in optimized vision.

Macromers/polymers are not visible in the lens, and graphic is used only as an illustration.

The Importance of ActivShield Technology

ActivShield is a UV protection layer built into the Light Adjustable Lens. Along with the RxSight UV-protective glasses, ActivShield helps prevent accidental sunlight exposure from changing the lens prior to the final lock-in treatment.

Don’t Get Left in the Dark

Peer Insights. Patient Experience. Practice Performance. 

Because every practice is different—and every patient’s vision matters. Let’s explore what’s measurable for your practice. Fill out the form to connect with a specialist and see how this could work for your practice. 

HCP Download
  1. Watanabe K, Negishi K, Kawai M, et al. Effect of experimentally induced astigmatism on functional, conventional, and low-contrast visual acuity. J Refract Surg. 2013;29(1):19-24.
  2. RxSight P160055: FDA Summary of Safety and Effectiveness Data. 2017.
  3. Sandoval HP, Donnenfeld ED, Kohnen T, et al. Modern laser in situ keratomileusis outcomes. J Cataract Refract Surg. 2016;42(8):1224-1234.
  4. 2025 RxSight Customer Survey.
LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

The Light Adjustable Lens provides optimized vision for patient satisfaction.2

Light Adjustable Lens patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

Since the Light Adjustable Lens is a monofocal lens, there is low risk of dysphotopsias caused by splitting light, leading to potentially enhanced vision and patient satisfaction.

LAL patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The Light Adjustable Lens offers LASIK-like accuracy in cataract surgery.2,3

92% of eyes (N = 391) achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE).

Patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The study was a prospective, controlled, multicenter, 12-month study of 600 patients (ITT population) randomized to receive implantation with the RxSight LAL (N = 403) or a commercially available monofocal IOL (N = 197). Effectiveness analyses included 391 LAL patients and 193 control patients. Primary safety variables included best spectacle-corrected visual acuity (BSCVA) at 6 months and incidence of sight-threatening complications and adverse events. Primary effectiveness variables included percent reduction in manifest cylinder at 6 months, percent mean absolute reduction in MRSE at 6 months, and rotation of meridian of LAL at 6 months. Percent of eyes with an uncorrected visual acuity (UCVA) of 20/20 or better at six months post-operatively compared between the LAL treatment group and the monofocal control group was a secondary endpoint.

The Light Adjustable Lens corrects as low as 0.50 D of astigmatism, which is the lowest level approved to be treated.

The ability to treat 0.50 D of postoperative cylinder makes the Light Adjustable Lens the only IOL in the United States approved to correct this level of vision-altering astigmatism. Astigmatism of as little as 0.50 D can reduce visual acuity by one line, and the impact on dynamic, functional visual acuity and low-contrast acuity is even greater.1